QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases with unmet medical need, completed enrollment of the 50 patients required for the interim analysis in its 80-patient confirmatory Phase 3 FLASH2 study evaluating HyBryte (TM) in cutaneous T-cell lymphoma. The interim analysis is slated for the second quarter of 2026, with topline data expected in the second half of the year. The Company noted an overall blinded response rate of 48 percent among patients who have completed treatment to date, exceeding the anticipated 25 percent rate used in the study’s powering assumptions. Investigators report safety findings consistent…